Volume 2, Issue 3 p. 205-218
Overview

Delivery of DNA vaccines: an overview on the use of biodegradable polymeric and magnetic nanoparticles

Sue D. Xiang

Corresponding Author

Sue D. Xiang

Department of Immunology, Central Clinical School, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria 3004, Australia

Department of Immunology, Central Clinical School, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria 3004, AustraliaSearch for more papers by this author
Cordelia Selomulya

Cordelia Selomulya

Department of Chemical Engineering, Monash University, Clayton, Victoria 3800, Australia

Search for more papers by this author
Jenny Ho

Jenny Ho

Department of Chemical Engineering, Monash University, Clayton, Victoria 3800, Australia

Search for more papers by this author
Vasso Apostolopoulos

Vasso Apostolopoulos

Immunology and Cancer Vaccine Laboratory, Burnet Institute, Melbourne, Victoria 3004, Australia

Search for more papers by this author
Magdalena Plebanski

Magdalena Plebanski

Department of Immunology, Central Clinical School, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria 3004, Australia

Search for more papers by this author
First published: 05 April 2010
Citations: 59

Abstract

Vaccination offers a cost-effective approach to the control of endemic infectious and a less invasive treatment modality against cancers. Since the discovery that injecting DNA encoding antigens (expressed in vivo) results in the induction of CD8 T cells as well as antibody mediated immunity, researchers have tried to develop methods to consistently enhance this immunity to disease protective levels in humans. Adsorption, coformulation, or encapsulation with particles has been found to both stabilize DNA formulations, through preventing rapid degradation, and provide vaccine adjuvanting effects, largely due to effective uptake of particulate materials by antigen presenting cells. Recently, it has been shown that nanoparticles, as opposed to microparticles, based DNA vaccine carriers are preferentially taken up by dendritic cells resulting in the induction of maximal levels of combined humoral and cellular immunity. WIREs Nanomed Nanobiotechnol 2010 2 205–218

This article is categorized under:

  • Therapeutic Approaches and Drug Discovery > Emerging Technologies
  • Therapeutic Approaches and Drug Discovery > Nanomedicine for Infectious Disease
  • Toxicology and Regulatory Issues in Nanomedicine > Toxicology of Nanomaterials